Yes, macular degeneration has a strong genetic component. If you have a sibling with age-related macular degeneration (AMD), your risk is roughly twelve times higher than someone without that family history, and the risk climbs even higher when a parent is affected. But genetics alone don’t seal your fate. AMD is a complex disease where inherited risk interacts with age, diet, smoking, and other environmental factors to determine whether, and how severely, the condition develops.
The Two Genes That Matter Most
Dozens of genes have been linked to AMD, but two stand out as the strongest drivers of inherited risk: the complement factor H gene (CFH) and the age-related maculopathy susceptibility 2 gene (ARMS2). Carrying high-risk versions of either one meaningfully increases your chances of developing the disease.
CFH provides instructions for a protein that keeps your immune system’s inflammatory response in check. Specifically, it helps regulate a part of your immune defense called the complement system, which attacks damaged cells and foreign invaders. When CFH carries a particular variation known as H402, the protein it produces doesn’t bind as effectively to structures in the thin membrane beneath the retina. The result is a buildup of fatty deposits and oxidative waste products in that membrane, which accelerates the formation of drusen, the yellowish deposits under the retina that are a hallmark of early AMD. The H402 variant also does a poorer job neutralizing inflammatory molecules, allowing chronic, low-grade inflammation to quietly damage retinal cells over decades.
ARMS2 is less well understood, but it appears to play a role in maintaining the structural tissue beneath the retina and protecting cells against oxidative stress. Research suggests it may also feed into the same complement system that CFH regulates, meaning both major risk genes converge on the same inflammatory pathway.
How AMD Runs in Families
AMD doesn’t follow a simple one-gene inheritance pattern the way some diseases do. You won’t find a single mutation that guarantees the condition. Instead, AMD risk comes from the combined effect of many common genetic variants, each contributing a small or moderate amount of risk. You can inherit high-risk versions of CFH from one or both parents, carry risk variants in ARMS2, and still never develop the disease if other factors work in your favor.
That said, the family clustering is real and significant. Research led by Shahid and colleagues found the twelve-fold increase in risk among siblings of AMD patients, which is one of the strongest familial associations seen in any common eye disease. This doesn’t mean AMD is inevitable if your family is affected, but it does mean family history is one of the most useful early warning signs available.
Rare Variants With Outsized Effects
Beyond the common risk genes, researchers at the National Institutes of Health have identified extremely rare mutations that carry a much stronger punch. In four families with AMD, scientists found mutations in genes that code for proteins called C8-alpha and C8-beta. These proteins are part of a structure called the membrane attack complex, the immune system’s final weapon for destroying damaged or infected cells. The mutations altered how the C8 proteins attach to each other, producing malformed versions that destabilize the attack complex. Whether the result is too much or too little activity from this complex, the outcome is the same: chronic, destructive inflammation in the retina that drives AMD progression.
These rare variants are unusual. Most people with AMD carry the more common risk variants described above. But studying these families has helped clarify that uncontrolled immune activity in the retina sits at the core of AMD, regardless of which specific gene is involved.
Diet and Smoking Interact With Your Genes
One of the most practical findings in AMD genetics is that lifestyle doesn’t affect everyone’s risk equally. Your genetic makeup influences how much benefit you get from a healthy diet.
Data from the Age-Related Eye Disease Study (AREDS) showed that people who followed a Mediterranean-style diet, rich in fish, vegetables, olive oil, and nuts, were less likely to develop advanced AMD. But this protective effect was concentrated among people who carried at least one protective version of the CFH gene. Those with only high-risk CFH variants didn’t see the same benefit from diet alone. This doesn’t mean diet is pointless if you carry risk genes, but it does suggest that the interaction between genetics and nutrition is more nuanced than a simple “eat well and you’ll be fine” message.
Smoking is the single strongest modifiable risk factor for AMD, and it interacts with genetics in a particularly unfavorable way. People who carry mutations in genes like CFH and NOS2A face a significantly amplified risk when they also have a smoking history. Perhaps more sobering, research shows little reduction in AMD risk even 15 or more years after quitting. The damage from smoking appears to compound with genetic vulnerability in ways that are difficult to reverse.
Juvenile Macular Degeneration Is Different
When people search about the genetics of macular degeneration, they sometimes mean Stargardt disease, the most common form of juvenile macular degeneration. This condition is genetically distinct from AMD. Stargardt disease is most often caused by mutations in the ABCA4 gene and follows an autosomal recessive inheritance pattern, meaning a child must inherit a defective copy from both parents to develop the disease. Parents who each carry one copy are typically unaffected themselves.
A less common form of Stargardt disease is caused by mutations in the ELOVL4 gene and follows an autosomal dominant pattern, where inheriting just one copy of the altered gene is enough. Unlike AMD, which typically appears after age 50 and involves many genes, Stargardt disease usually begins in childhood or early adulthood and traces back to a single gene.
Should You Get Genetic Testing?
The American Academy of Ophthalmology does not currently recommend genetic testing for AMD. The reasoning is straightforward: no gene therapy exists to prevent or treat the disease, so identifying your specific risk variants wouldn’t change your clinical care. Your eye doctor will monitor you and recommend treatments based on the stage and type of AMD you have, not on which genes are involved.
What family history can do, though, is motivate earlier and more frequent screening. If AMD runs in your family, regular dilated eye exams become more important starting in your 50s (or earlier if you have other risk factors like smoking). Catching the disease in its early, dry stage gives you more time to adopt protective habits and begin monitoring for any progression to the more damaging wet form. Globally, AMD cases more than doubled between 1990 and 2021, rising from about 3.6 million to over 8 million, driven largely by aging populations. The genetic risk hasn’t changed, but the number of people living long enough to express that risk has.